Tempus AI

The stock of Tempus AI climbed nearly 15% to $80.36, reaching a new year high. Market participants view this as a reaction to the company’s growth potential, the acquisition of Personalis, and comments by Eric Lefkofsky on AI in healthcare. Technically, the breakout above the August high on heavy volume delivered a clear buy signal, and analysts had already issued buy recommendations. Tempus AI benefits from its growing dataset for personalized medicine, which is expected to gain importance over the long term. » Więcej na deraktionaer.de

Tempus AI shares surged about 30% this week after Morgan Stanley highlighted reimbursement pricing that could add $330 million to $400 million in annual revenue from xT and xF diagnostics. CEO Eric Lefkofsky said the company should exceed its 25% multiyear growth target, citing roughly $200 million in Q2 data licensing bookings from AstraZeneca, GSK and Merck. Management raised FY guidance and reiterated a path to positive free cash flow, though the stock still trades below its 52-week high and carries high beta and ongoing GAAP losses. » Więcej na finance.yahoo.com

Tempus AI's stock climbed about ten percent on Tuesday after founder and CEO Eric Lefkofsky emphasized that healthcare is likely to benefit most from AI. Tempus combines diagnostics and data services and uses extensive datasets and large AI models to improve diagnostics and help pharma companies develop drugs. The company has a market capitalization of roughly $12 billion and is aiming to grow in precision oncology with the planned acquisition of Personalis; a break above the August high would open up further upside potential. » Więcej na deraktionaer.de